BH3 mimetics also synergized with other on-target therapies such as inhibitors of oncogenic kinases that often induce upregulation of pro-apoptotic BH3-only proteins BIM, PUMA, or BMF and shifts between BCL-2 prosurvival dependence in cancer cells. This evidence concerns the gene BCL2 and cancer.